News articles about Henry Schein (NASDAQ:HSIC) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Henry Schein earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.3710584742778 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the headlines that may have impacted Accern’s scoring:
- ETFs with exposure to Henry Schein, Inc. : December 22, 2017 (finance.yahoo.com)
- Henry Schein (HSIC) Acquires eVetPractice – StreetInsider.com (streetinsider.com)
- Henry Schein To Present At The 36th Annual J.P. Morgan Healthcare Conference (finance.yahoo.com)
- Henry Schein Buys eVetPractice, Boosts Technology & VAS Arm (finance.yahoo.com)
- Henry Schein buys vet practice management software provider (seekingalpha.com)
Several equities research analysts have recently weighed in on HSIC shares. Credit Suisse Group reissued a “hold” rating and issued a $87.50 target price on shares of Henry Schein in a research note on Tuesday, August 29th. Piper Jaffray Companies raised shares of Henry Schein from a “neutral” rating to an “overweight” rating in a research note on Friday, September 15th. UBS Group reissued a “buy” rating on shares of Henry Schein in a research note on Friday, September 15th. Royal Bank of Canada started coverage on shares of Henry Schein in a research note on Tuesday, September 19th. They issued a “sector perform” rating and a $91.00 target price on the stock. Finally, Morgan Stanley started coverage on shares of Henry Schein in a research note on Thursday, September 21st. They issued an “equal weight” rating and a $88.00 target price on the stock. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the company’s stock. Henry Schein currently has a consensus rating of “Hold” and a consensus price target of $87.79.
Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.87 EPS for the quarter, missing the Zacks’ consensus estimate of $0.90 by ($0.03). The company had revenue of $3.16 billion during the quarter, compared to the consensus estimate of $3.05 billion. Henry Schein had a return on equity of 19.71% and a net margin of 4.52%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.84 earnings per share. research analysts forecast that Henry Schein will post 3.6 earnings per share for the current year.
Henry Schein declared that its Board of Directors has initiated a stock buyback program on Monday, September 18th that allows the company to buyback $400.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 6.3% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.
In other Henry Schein news, Director Barry J. Alperin sold 5,796 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $70.76, for a total transaction of $410,124.96. Following the transaction, the director now directly owns 48,172 shares in the company, valued at approximately $3,408,650.72. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.19% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This report was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2017/12/23/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-henry-schein-hsic-stock-price.html.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
What are top analysts saying about Henry Schein? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Henry Schein and related companies.